Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.
| Revenue (Most Recent Fiscal Year) | $638.50M |
| Net Income (Most Recent Fiscal Year) | $-183.17M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 13.39 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 122.63 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -24.61% |
| Net Margin (Trailing 12 Months) | -24.68% |
| Return on Equity (Trailing 12 Months) | -265.55% |
| Return on Assets (Trailing 12 Months) | -28.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.43 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.34 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.52 |
| Inventory Turnover (Trailing 12 Months) | 1.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.99 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 52.38M |
| Free Float | 41.59M |
| Market Capitalization | $10.40B |
| Average Volume (Last 20 Days) | 0.65M |
| Beta (Past 60 Months) | 0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 20.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 81.49% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |